Background: SGLT2 is a class of oral antidiabetic agents that act on sugar transport: they help to increase the rate of Glucose elimination by urine. SGLT2 inhibitors have received attention because of the affords treating type 2 diabetes and may improve cardiovascular and renal outcome. Objectives: To assess the relationship between the use of SGLT2 inhibitors and the degree of glycosuria in 100 patients with diabetes taking treatment at HMC Peshawar. Study design: A descriptive cross-sectional study Place and duration of study. Department of endocronolgy hmc Peshawar from jan 2022 to jan 2023 Methods : The current study is a descriptive cross-sectional study with the participants being selected from 100 patients with T2DM at the Department of Endocrinology HMC Peshawar between January 2022 to January 2023. SGLT2 inhibitors were prescribed to the patients; glycosuria levels were assessed before the treatment and then, on a schedule. In comparing the rates, the standard mean glycosuria with its standard deviation, as well as the p values, are indicated in the statistical rates. Results : It pointed out that SGLT2 inhibitor usage was proportional to the levels of glycosuria detected in the patients’ urine samples. The overall mean of the daily level of glycosuria rose by 45. 3 g/day (± 12. 7 g/day) above the baseline level. The variability of the levels of glycosuria was measured using the standard deviation which was found to be 12. 7. The p-value of 0. 002 indicated that SGLT2 inhibitors contributed to increased glycosuria and the present analysis thus confirmed the effectiveness of the given drugs. Conclusion : Based on the Study, it is ascertained that SGLT2 inhibitors increases glycosuria in T2DM patients in a manner that speaks well for glycemia management. The relationship between the use of SGLT2 inhibitors and glycosuria shows that they are useful drugs in glycometabolic management.